Johnson & Johnson's second-quarter 2018 earnings call highlighted several positive and some mixed elements that are likely to influence the stock price in the short term.

### Positive Factors:
- **Strong Pharmaceutical Performance**: The Pharmaceutical segment showed outstanding growth, with a 17.6% increase in sales, driven by products like DARZALEX, IMBRUVICA, and ZYTIGA. This segment's performance is expected to continue strong despite some challenges like biosimilar competition[5].
- **Operational Sales Growth**: Overall operational sales grew 8.7%, and adjusted diluted EPS increased by 14.8%, exceeding analyst estimates. The company raised its full-year sales and EPS guidance, indicating confidence in future performance[3][5].
- **Innovation and Pipeline**: The company emphasized its commitment to innovation, with significant R&D investments and a robust pipeline, including new product launches and acquisitions. This suggests long-term growth potential[5].
- **Management Changes and Leadership**: The promotion of experienced leaders to key roles, such as Jennifer Taubert and Ashley McEvoy, is seen as positive for the company's future direction and execution[5].

### Mixed and Negative Factors:
- **Consumer Segment Performance**: The Consumer segment's sales were below expectations due to one-time factors, although the company is optimistic about a stronger second half with new product launches[5].
- **Medical Devices Challenges**: While the Medical Devices segment showed some improvement, particularly in Vision and Electrophysiology, areas like Spine and Knees are still struggling. However, new product launches and improved execution are expected to drive better performance in the second half[5].
- **Pricing Pressure**: The company faced pricing pressure in several segments, including Orthopedics and Pharmaceuticals, which could continue to impact margins[5].
- **External Factors**: Concerns around global trade, healthcare costs, and drug pricing were addressed, but these are ongoing issues that may continue to pose risks[5].

### Conclusion:
Given the strong pharmaceutical performance, increased operational sales growth, and positive guidance updates, the overall sentiment from the earnings call is positive. However, the challenges in the Consumer and Medical Devices segments, along with ongoing pricing pressures and external factors, may temper some of the enthusiasm.

### Rating:
1

This rating reflects a positive impact on the stock price due to the strong earnings performance and optimistic guidance, albeit with some caution due to the mixed results in certain segments and ongoing external challenges.